Christine M. Colvis serves as Director of the Office of Drug Development Partnership Programs (ODDPP) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health. The office leads a broad portfolio focused on accelerating therapeutic discovery and early-stage development through innovative partnerships, data-driven approaches, and cross-sector collaboration. Her office spans activities from expanding the target landscape through clinical evaluation as well as catalyzing the development of high-impact, next-generation tools and platforms that will improve the efficiency of diagnostic and therapeutic development. The small office also oversees biomedical AI and AI-enabling initiatives, including the Biomedical Data Translator program and LitCoin.

Colvis also serves as Acting Director of the NCATS Office of Special Initiatives, which leads transformative programs including microphysiological systems (“tissue chips”), automated chemistry platforms, quantum-enabled biomedical applications, advanced diagnostic technologies, and novel biomarker strategies.

Through extensive collaborations across NIH, federal partners such as FDA, CMS and NASA, as well as industry, Dr. Colvis advances innovative strategies to make translational science faster, more predictive, and more efficient.

Pamela Hill is a seasoned biopharmaceutical leader with more than two decades of experience advancing scientific innovation, external partnerships, and early stage drug discovery. As Head of Open Innovation at AstraZeneca, she leads an externally aligned program that elevates the company’s global scientific reputation, expands access to external expertise, and delivers meaningful impact across preclinical and clinical portfolios.

Hill is widely recognized as a trusted collaborator and expert in academic engagement, public–private partnerships, and cross functional leadership, drawing on her extensive scientific background and early career contributions leading antiviral and antibacterial discovery programs through candidate selection. Her work has established AstraZeneca as a longstanding industry leader in Open Innovation, and her influence extends beyond R&D through her deep commitment to mentoring, community engagement, and STEM outreach.